-+ 0.00%
-+ 0.00%
-+ 0.00%

Scotiabank Maintains Sector Outperform on Arcturus Therapeutics, Raises Price Target to $35

Benzinga·07/02/2025 14:24:45
Listen to the news
Scotiabank analyst Greg Harrison maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Sector Outperform and raises the price target from $32 to $35.